Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAC Ebola vaccine trial
PACTR201712002760250Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2017
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 4
01
Overview
Randomised trial of zabdeno, Mvabea, Ebola Zaire vaccine (live, attenuated) and sodium chloride in Ebola virus disease (EVD) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Planned start Mar 2017; status: not yet recruiting.
02
Drugs
zabdenoMvabeaEbola Zaire vaccine (live, attenuated)sodium chloride
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR201712002760250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201712002760250.